Samer Choucair: Alzheimer’s Leaves Its Mark on the Brain Seven Years Earlier Medicine Faces a New Investment Race
Investment leader Samer Choucair said a new study published in Nature Neuroscience is opening a potentially important new frontier for investment in the early detection of Alzheimer’s disease, after researchers found that changes in cortical thickness can be detected at least seven years before individuals reach high levels of amyloid detectable by PET imaging.
Published on August 19, 2026, the study combined longitudinal MRI and amyloid-PET data from three cohorts of cognitively healthy adults. Researchers analyzed 4,570 MRI scans from 1,051 individuals, alongside 1,684 amyloid-PET scans from 691 participants. Individuals who later became amyloid-positive showed differences in cortical thickness and its trajectory years before reaching the PET-defined threshold for elevated amyloid.
For Samer Choucair, the significance of the finding is not that MRI can now replace PET, nor that cortical-thickness changes alone can diagnose Alzheimer’s disease. Rather, its importance lies in the possibility that the window for identifying biological changes associated with the disease could move substantially earlier.
That shift could eventually redistribute value across the neurological-care ecosystem, moving part of the opportunity beyond pharmaceuticals and into medical imaging, AI-powered image analysis, biomarkers, blood testing, diagnostics, and clinical decision-support technologies.
Seven Years Could Change the Economics of Detection
Choucair said the study potentially changes one of the most important questions in Alzheimer’s medicine: how early can meaningful biological changes be detected?
Researchers found that people who later developed elevated amyloid had a relatively thicker cortex and experienced less cortical thinning than individuals who remained amyloid-negative. Importantly, these differences were detectable in MRI scans taken at least seven years before participants crossed the threshold for amyloid positivity on PET.
The researchers themselves caution against interpreting these findings as a ready-made diagnostic test. The study improves understanding of the biological sequence preceding detectable amyloid pathology, but additional research would be required before cortical-thickness measurements could become a clinical screening tool.
For investors, however, Samer Choucair argues that the direction of travel matters.
If neurological risk can eventually be identified earlier and more efficiently, healthcare systems could begin shifting from a model dominated by late diagnosis and long-term disease management toward one involving earlier risk stratification, targeted testing, and potentially earlier therapeutic intervention.
The Economic Incentive Is Enormous
The global healthcare system has a powerful financial incentive to make that transition.
The World Health Organization estimates that more than 55 million people worldwide are living with dementia, with the number projected to reach approximately 78 million by 2030 and 139 million by 2050.
The investment opportunity surrounding early detection therefore extends far beyond the pharmaceutical market.
Dementia creates costs across hospitals, long-term care, families, caregivers, public healthcare budgets, and labor productivity. WHO data indicate that dementia already costs the global economy more than $1 trillion annually.
For Choucair, that makes early detection economically significant even before considering the commercial value of new treatments.
The larger investment question is whether earlier identification can ultimately allow healthcare systems to intervene more efficiently, target expensive diagnostic procedures toward higher-risk patients, and connect those patients with treatments at stages where intervention may be more meaningful.
Blood Tests Are Already Changing the Diagnostic Market
The diagnostic transformation is no longer theoretical.
In May 2025, the U.S. Food and Drug Administration cleared for marketing the first blood test used to aid in diagnosing Alzheimer’s disease. The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio measures two proteins in blood and calculates a ratio correlated with the presence or absence of amyloid plaques in the brain.
The distinction is critical, however. The test is intended for adults aged 55 and older who already exhibit signs and symptoms of Alzheimer’s disease. It is not intended as a screening test for cognitively healthy people.
For Samer Choucair, this illustrates how the economics of Alzheimer’s diagnosis could evolve.
Rather than relying exclusively on expensive and relatively scarce diagnostic procedures, healthcare systems could eventually develop a layered model in which lower-cost blood biomarkers and algorithmic risk assessment identify patients requiring further investigation, while MRI, PET imaging, specialist testing, and clinical evaluation provide progressively higher levels of confirmation.
That would create an entire diagnostic value chain rather than a single winning technology.
AI Could Become the Connecting Layer
Choucair believes artificial intelligence could become particularly important if structural brain imaging ultimately proves capable of revealing clinically useful information earlier in the disease process.
Healthcare systems already generate enormous volumes of MRI data. The investment opportunity would therefore not necessarily depend on building entirely new imaging infrastructure.
Part of the opportunity could come from extracting more information from scans already being performed.
Advanced algorithms capable of measuring subtle changes in cortical structure, combining those signals with blood biomarkers and clinical history, and identifying which patients require more specialized testing could potentially make existing healthcare infrastructure more productive.
The economic value would then move toward platforms capable of integrating multiple forms of medical data rather than simply producing one test result.
That could create opportunities across medical imaging software, diagnostic AI, laboratory testing, healthcare data infrastructure, clinical-trial recruitment, and precision medicine.
Saudi Arabia and the Early-Diagnosis Opportunity
Choucair said the same transition could become increasingly relevant in Saudi Arabia as the population ages and the healthcare system continues its digital transformation.
Saudi Ministry of Health information cites approximately 130,000 Alzheimer’s cases in the Kingdom, highlighting the potential long-term demand for dementia-related healthcare services.
For Saudi Arabia, the investment opportunity therefore extends beyond importing new Alzheimer’s drugs.
Earlier diagnosis could support the development of domestic health-technology platforms, specialized imaging centers, medical-data infrastructure, laboratory diagnostics, AI-assisted radiology, clinical research, and partnerships with international pharmaceutical and biotechnology companies.
Building those capabilities could also strengthen Saudi Arabia’s position as a regional center for clinical research and precision medicine.
For Samer Choucair, the strategic advantage would come from connecting diagnostics, data, imaging, research, and treatment into a single healthcare ecosystem rather than treating each as an isolated investment.
The Next Alzheimer’s Investment Race
Choucair cautioned that the Nature Neuroscience study does not mean routine MRI screening for every healthy adult is imminent.
Nor does a change in cortical thickness establish that an individual has Alzheimer’s disease. The research demonstrates that measurable structural differences can precede PET-detectable high amyloid levels by years, but translating that finding into validated clinical screening requires further research.
That distinction is particularly important for investors because medical breakthroughs and commercially scalable healthcare products do not move on the same timetable.
Scientific discovery must still pass through validation, regulation, clinical adoption, reimbursement, physician acceptance, and integration into healthcare systems before it becomes a durable commercial market.
Yet the direction is becoming clearer.
The Alzheimer’s economy is gradually expanding beyond the traditional race to develop treatments. A parallel race is emerging to determine who can identify risk earlier, more accurately, more cheaply, and at sufficient scale to influence medical decisions.
“The study does not tell us that routine screening of healthy populations is around the corner, nor does cortical thickness alone prove that someone has Alzheimer’s,” Samer Choucair said. “But it changes the investment question. The companies that can identify risk earlier and translate that information into a scalable clinical decision will be better positioned for the next phase of the Alzheimer’s economy.”
For investors, that may ultimately be the larger significance of the seven-year window.
If Alzheimer’s leaves measurable biological signals years earlier than previously assumed, the next major healthcare opportunity may not begin with treating the disease after diagnosis. It may begin much earlier with the technologies capable of finding its earliest detectable footprint.